Stockscreener 앱 받기
0.2989
18.99%
0.0477
시간 외 거래:
.29
-0.0089
-2.98%
전일 마감가:
$0.2512
열려 있는:
$0.26
하루 거래량:
4.18M
Relative Volume:
1.83
시가총액:
$59.15M
수익:
$74,000
순이익/손실:
$-13.43M
주가수익비율:
-0.0318
EPS:
-9.4
순현금흐름:
$-10.54M
1주 성능:
+4.77%
1개월 성능:
+39.67%
6개월 성능:
-32.39%
1년 성능:
-85.06%
1일 변동 폭
$0.2509
$0.328
1주일 범위
$0.225
$0.41
52주 변동 폭
$0.1706
$3.0835
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
명칭
Cyclacel Pharmaceuticals Inc
전화
908-517-7330
주소
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
CYCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.2989 | 59.15M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2020-04-27 | 재개 | ROTH Capital | Buy |
| 2018-09-07 | 개시 | Ladenburg Thalmann | Buy |
| 2015-10-16 | 개시 | H.C. Wainwright | Buy |
| 2010-02-04 | 개시 | Roth Capital | Buy |
| 2009-10-28 | 개시 | Merriman | Buy |
| 2008-08-12 | 개시 | Piper Jaffray | Buy |
| 2008-03-12 | 재확인 | Cantor Fitzgerald | Buy |
| 2008-03-12 | 재확인 | Collins Stewart | Buy |
| 2008-03-12 | 재확인 | Needham & Co | Buy |
| 2007-11-27 | 재확인 | Cantor Fitzgerald | Buy |
| 2007-08-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2007-06-04 | 재확인 | Needham & Co | Buy |
| 2007-04-23 | 개시 | Lazard Capital | Buy |
| 2007-04-10 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Cyclacel Pharmaceuticals Inc 주식(CYCC)의 최신 뉴스
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com - Defense World
Stocks of Cyclacel Pharmaceuticals Inc (CYCC) are poised to climb above their peers - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Examining Cyclacel Pharmaceuticals Inc (CYCC) more closely is necessary - uspostnews.com
The Psychology of Cyclacel Pharmaceuticals Inc Inc. (CYCC) Price Performance: Understanding Market Sentiment - investchronicle.com
Cyclacel Pharmaceuticals (CYCC) Announces Quarterly Dividend - GuruFocus
Cyclacel Pharmaceuticals expands share authorization By Investing.com - Investing.com India
Cyclacel Pharmaceuticals expands share authorization - Investing.com
Major Shareholders Set to Sell Stocks; Company (TICKER) to Reap No Proceeds | CYCC Stock News - GuruFocus
Cyclacel Pharmaceuticals Inc Inc. (CYCC) Price Performance: A Technical Analysis Perspective - investchronicle.com
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Could Actually Go To 1 In 12 Months - Marketing Sentinel
Was Cyclacel Pharmaceuticals Inc (CYCC)’s session last reading good? - uspostnews.com
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Trading (CYCCP) With Integrated Risk Controls - news.stocktradersdaily.com
Cyclacel Pharmaceuticals announces preferred stock dividend By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals announces preferred stock dividend - Investing.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
When (CYCCP) Moves Investors should Listen - news.stocktradersdaily.com
Cyclacel Pharmaceuticals Inc (CYCC) Q2 2024 Earnings Call Transc - GuruFocus
Fitters Diversified To Dispose Subsidiary To Nasdaq Listed Pharma Firm - businesstoday.com.my
Fitters plans to sell full stake in unit to US biotech firm - The Malaysian Reserve
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development - TipRanks
Cyclacel Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift - TipRanks
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update - MarketScreener
Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks
CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com - Investing.com South Africa
CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle
(CYCCP) Trading Advice - news.stocktradersdaily.com
Cyclacel Pharmaceuticals (CYCC) Projected to Post Earnings on Tuesday - The AM Reporter
CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Inc (CYCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):